CN/EN

All
  • All
  • Product Management
  • News and Information
  • Introduction content
  • Business outlets
  • Frequently Asked Questions
  • Corporate Video
  • Corporate Portfolio

Recently, Attorney Su Zhongming, Director of the Compliance Practice Center at Beijing Starrise Law Firm, was invited by Sinopharm Zhonglian Pharmaceutical Co., Ltd. to deliver a specialized training session titled “The Impact of Judicial Interpretation (II) on Corruption and Bribery on the Compliant Operations of Pharmaceutical Enterprises.” Centered on the “Interpretation (II) of the Supreme People’s Court and the Supreme People’s Procuratorate on Several Issues Concerning the Application of Law in Handling Criminal Cases of Corruption and Bribery,” which officially came into effect on May 1, 2026, Attorney Su provided a systematic presentation covering three key dimensions: the legislative evolution, an in-depth analysis of pivotal statutory provisions, and strategic approaches to compliance for pharmaceutical companies. Leaders, employees, and external partners of Sinopharm Zhonglian attended the training, underscoring Xinglai Law Firm’s dedicated commitment to corporate compliance and its role in helping state-owned enterprises mitigate legal risks.



Su Zhongming

Director of the Compliance Practice Center at Beijing Starrise Law Firm


During the training, Attorney Su Zhongming, drawing on typical scenarios in the pharmaceutical industry, provided an in-depth analysis of the key changes introduced by Interpretation No. 2: the pharmaceutical sector has been designated as a statutory priority for enhanced penalties; the threshold for criminalizing corporate bribery has been halved from RMB 200,000—applicable to ordinary industries—to RMB 100,000–200,000; covert forms of benefit transfer, such as using CSOs to siphon funds or fabricating lecture fees to extract cash, will now be directly prosecuted as bribery; and judicial authorities will conduct penetrating investigations into the flow of funds and the attribution of benefits, effectively closing off avenues for evading liability by “masking personal interests under the guise of corporate conduct.” Attorney Su emphasized that regulatory oversight in the pharmaceutical industry has evolved into an integrated “four‑pronged” framework encompassing criminal, administrative, industry‑specific sanctions, and credit‑based evaluation. The regulatory logic has expanded from targeting bribery at the hospital level to addressing intermediary practices within professional associations, and further to tackling bribery at the corporate level, creating a comprehensive end‑to‑end closed loop. Non‑compliant companies not only face substantial financial penalties and imprisonment for responsible individuals but also risk losing their eligibility to operate in core markets, incurring irreversible legal and commercial costs. Pharmaceutical enterprises have thus moved beyond the era of unregulated, “money‑in‑exchange‑for‑sales” growth; compliant operations have become an indispensable baseline for survival and development, and any attempt to take chances will expose firms to severe legal and operational risks.


In addition, Attorney Su Zhongming provided a comprehensive overview of compliance strategies for pharmaceutical companies operating in the new regulatory landscape, covering end-to-end oversight of third-party collaborations, meticulous financial accounting, compliance in academic promotion and client hospitality, procurement‑tendering risk management, and other key measures. He further recommended that pharmaceutical firms establish a three‑tier anti‑bribery governance framework—comprising decision‑making, oversight, and implementation levels—and proactively align with international standards such as ISO 37001 certification for anti‑bribery management, thereby elevating compliance from ad hoc initiatives to a holistic, enterprise‑wide system.


Training venue


Sinopharm Zhonglian is a time-honored Chinese brand under the Sinopharm Group, with a history spanning more than 70 years. Its core business encompasses the production of traditional Chinese medicines, the cultivation and processing of medicinal herbs, and the development of TCM formula granules, among other areas. The company boasts 330 registered products and operates 68 medicinal herb cultivation bases. In recent years, as anti-corruption efforts in the pharmaceutical sector have continued to intensify, Sinopharm Zhonglian has placed great emphasis on building a robust compliance framework, integrating compliance principles into every stage and link of its production and operations. This training session precisely addressed the compliance‑management challenges faced by enterprises in the context of the new regulations outlined in Interpretation No. 2, providing professional support for the company to further strengthen its risk‑prevention and control system.


The Compliance Practice Center of Beijing Starrise Law Firm has long been dedicated to corporate compliance legal services, amassing extensive practical experience in building compliance frameworks and mitigating criminal risks across sectors such as pharmaceuticals and healthcare, finance, and energy. Attorney Su Zhongming stated that, going forward, Xinglai Law Firm will continue to leverage its professional expertise to support the development of the real economy, helping more enterprises fortify their compliance defenses and ensuring the steady, sustainable growth of both private and state‑owned enterprises through the rule of law.


Attorney Profile

.

Su Zhongming

Beijing Starrise Law Firm
Director of the Compliance Business Center

Bachelor of Laws from Jilin University and Master of International Law. Awarded among the Top 15 Compliance Lawyers Preferred by Clients in LEGALBAND’s 2025 rankings, named one of the Top 20 Client‑Recommended Lawyers (Beijing–Tianjin–Hebei) in Lvxin Society’s 2025 Power List, and recognized with the “Crown” Classic Case award at the 10th Guike Annual Conference, among other honors. Among the first cohort of corporate executives to obtain the Senior Corporate Compliance Professional certification. With over a decade of experience in legal affairs, asset management, and risk control and compliance across sectors such as guarantees and financial leasing, he has amassed extensive expertise in corporate investment and financing due diligence, hands‑on financial leasing operations and risk management, and contract administration. Since joining Xinglai, he has led numerous projects to establish compliance management systems for cases involving regulatory matters, central state‑owned enterprises, public institutions, and private companies; spearheaded the construction of the Jiaxing City Compliance Demonstration Zone; and been frequently invited to deliver lectures and training sessions at numerous universities and major central state‑owned enterprises.


Editor and Layout: Wang Xin

Reviewed by: Shen Xinyu


Beijing Headquarters Address: No. 8, Jianguomen North Street, Dongcheng District, Beijing 17th Floor, China Resources Building
Contact numbers: 010-64011566, 18811162996


Wuhan Branch Address: Room 1001, 10th Floor, Huangpu International Center, Jiang’an District, Wuhan, Hubei Province

Contact number: 027-82288828



Hefei Branch Address: Rooms 1703–1710, Building E, Weilan Business Harbor, No. 188 Qianshan Road, Shushan District, Hefei, Anhui Province
Contact numbers: 0551-68127192, 15850561916

Related News

CONTACT US

Contact us


Beijing Headquarters

Address: 17th Floor, China Resources Building, No. 8 Jianguomen North Avenue, Dongcheng District, Beijing

Phone: 010-64011566

Email: contact@xinglailaw.com


Wuhan Branch Office

Address: Room 1001, Huangpu International Center, Zhaojiatiao, Jiang'an District, Wuhan City

Phone: 027-82288828

Email: admin@xinglailaw-wuhan.com


Hefei Branch Office

Address:Room 1703-1710, Building E, Weilan Business Port, No. 188 Qianshan Road, Shushan District, Hefei City

Phone: 15850561916

Email: contact@xinglailaw-hefei.com

.

Follow us

.

Digital Star Come

Case Consultation

Experienced lawyers offer free, no-obligation consultations to provide tailored solutions.


%{tishi_zhanwei}%

Copyright 2025 Beijing Xinglai Law Firm

Tags: Website Development:300.cn Beijing Certificate

Business license